News

STALICLA pre-IND meeting with FDA on STP1

STALICLA announces completion of pre-IND meeting with FDA on STP1 for subgroup of patients with Autism Spectrum Disorder (ASD)

Read more

Empresa emergente descobre nova forma de tratar autismo

Stalicla, uma startup genebrina, recorre a algoritmos para definir perfil biológico de cada grupo de autistas e, assim, identificar fármacos mais eficazes. O ensaio clínico do primeiro pacote terapêutico da empresa aguarda luz verde da agência reguladora de medicamentos dos Estados Unidos.

Read more

Lynn Durham joins expert panel at SACHS 12th European Life Sciences CEO Forum in Zurich

STALICLA SA’s CEO Lynn Durham joined a panel of leading industry experts at the SACHS European Life Sciences CEO Forum on February 25th-26th, 2019 in Zurich, Switzerland. The ‘Neuroscience BD&L’ panel which Lynn was part of, took place at 11:20am Monday 25th.

Read more

Search for content on Stalicla...